Mycophenolate mofetil and skin diseases

Lupus

Volumn 14, Issue SUPPL. 1, 2005, Pages

  Hartmann, M ^a   Enk, A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Dermatology; MMF; Skin diseases

Indexed keywords

ACICLOVIR; ANTIMALARIAL AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; STEROID; TACROLIMUS; VALACICLOVIR;

ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; AUTOIMMUNE DISEASE; BLISTER; BULLOUS DERMATITIS; DIARRHEA; ENDOCARDITIS; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; INFECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER TOXICITY; LUPUS ERYTHEMATOSUS; LYMPHOCYTE; LYMPHOCYTOPENIA; MOUTH ULCER; MYALGIA; NAIL DISEASE; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; PSORIASIS; SEPTICEMIA; SKIN DISEASE;

EID: 16244402995     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203305lu2121oa     Document Type: Article

References (78)

1. Epinette WW, Parker CM, Jones EL, Greist MC. Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol 1987; 17: 962-971.
2. Gabardi S, Tran JL, Clarkson MR. Enteric-coated mycophenolate sodium. Ann Pharmacother 2003; 37: 1685-1693.
3. Mimouni D, Anhalt GJ, Cummins DL, Kouba DJ, Thorne JE, Nousari HC. Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil. Arch Dermatol 2003; 139: 739-742.
4. Powell AM, Albert S, Al Fares S et al. An evaluation of the usefulness of mycophenolate mofetil in pemphigus. Br J Dermatol 2003; 149: 138-145.
5. Enk AH, Knop J. Treatment of pemphigus vulgaris with mycophenolate mofetil. Lancet 1997; 350: 494.
6. Enk AH, Knop J. Mycophenolate is effective in the treatment of pemphigus vulgaris. Arch Dermatol 1999; 135: 54-56.
7. Nousari HC, Sragovich A, Kimyai-Asadi A, Orlinsky D, Anhalt GJ. Mycophenolate mofetil in autoimmune and inflammatory skin disorders. J Am Acad Dermatol 1999; 40: 265-268.
8. Grundmann-Kollmann M, Korting HC, Behrens S et al. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol 1999; 40: 957-960.
9. Williams JV, Marks JG Jr, Billingsley EM. Use of mycophenolate mofetil in the treatment of paraneoplastic pemphigus. Br J Dermatol 2000; 142: 506-508.
10. Chams-Davatchi C, Nonahal AR, Daneshpazooh M et al. Open trial of mycophenolate mofetil in the treatment of resistant pemphigus vulgaris. Ann Dermatol Venereol 2002; 129: 23-25.
11. Katz KH, Marks JG Jr, Helm KF. Pemphigus foliaceus successfully treated with mycophenolate mofetil as a steroid-sparing agent. J Am Acad Dermatol 2000; 42: 514-515.
12. Bredlich RO, Grundmann-Kollmann M, Behrens S, Kerscher M, Peter RU. Mycophenolate mofetil monotherapy for pemphigus vulgaris. Br J Dermatol 1999; 141: 934.
13. Grundmann-Kollmann M, Kaskel P, Leiter U et al. Treatment of pemphigus vulgaris and bullous pemphigoid with mycophenolate mofetil monotherapy. Arch Dermatol 1999; 135: 724-725.
14. Böhm M, Beissert S, Schwarz T, Metze D, Luger T. Bullous pemphigoid treated with mycophenolate mofetil. Lancet 1997; 349: 541.
15. Nousari HC, Griffin WA, Anhalt GJ. Successful therapy for bullous pemphigoid with mycophenolate mofetil. J Am Acad Dermatol 1998; 39: 497-498.
16. Ratnam KV. Adjuvant therapy of bullous pemphigoid with mycophenolate mofetil: old drug, new use. Singapore Med J 2001; 42: 482-484.
17. Megahed M, Schmiedeberg S, Becker J, Ruzicka T. Treatment of cicatricial pemphigoid with mycophenolate mofetil as a steroid-sparing agent. J Am Acad Dermatol 2001; 45: 256-259.
18. Elser I, Selimovic D, Ruzicka T, Kuhn A, Megahed M. Mycophenolate mofetil as effective therapy option in scarring pemphigoid. Hautarzt 2003; 54: 981-984.
19. Glaser R, Sticherlin M. Successful treatment of linear IgA bullous dermatosis with mycophenolate mofetil. Acta Derm Venereol 2002; 82: 308-309.
20. Farley-Li J, Mancini AJ. Treatment of linear IgA bullous dermatosis of childhood with mycophenolate mofetil. Arch Dermatol 2003; 139: 1121-1124.
21. Burchardt T, Buchau A, Ruzicka T, Megahed M. IgA pemphigus. Successful treatment with mycophenolate mofetil. Hautarzt 2004; 55: 387-389.
22. Schattenkirchner S, Eming S, Hunzelmann N, Krieg T, Smola H. Treatment of epidermolysis bullosa acquisita with mycophenolate mofetil and autologous keratinocyte grafting. Br J Dermatol 1999; 141: 932-933.
23. Trebing D, Ziemer A. Acquired epidermolysis bullosa with a highly varied clinical picture and successful treatment with mycophenolate mofetil. Hautarzt 2001; 52: 717-721.
24. Kowalzick L, Suckow S, Ziegler H, Waldmann T, Ponnighaus JM, Glaser V. Mycophenolate mofetil in epidermolysis bullosa acquisita. Dermatology 2003; 207: 332-334.
25. Jones EL, Epinette WW, Hackney VC, Menendez L, Frost P. Treatment of psoriasis with oral mycophenolic acid. J Invest Dermatol 1975; 65: 537-542.
26. Marinari R, Fleischmajer R, Schragger AH, Rosenthal AL. Mycophenolic acid in the treatment of psoriasis: long-term administration. Arch Dermatol 1977; 113: 930-932.
27. Lynch WS, Roenigk HH Jr. Mycophenolic acid for psoriasis. Arch Dermatol 1977; 113: 1203-1208.
28. Haufs MG, Beissert S, Grabbe S, Schutte B, Luger TA. Psoriasis vulgaris treated successfully with mycophenolate mofetil. Br J Dermatol 1998; 138: 179-181.
29. Zhou Y, Rosenthal D, Dutz J, Ho V. Mycophenolate Mofetil (CellCept(R)) for Psoriasis: A Two-Center, Prospective, Open-Label Clinical Trial. J Cutan Med Surg 2003; 7: 193-197.
30. Geilen CC, Arnold M, Orfanos CE. Mycophenolate mofetil as a systemic antipsoriatic agent: positive experience in 11 patients. Br J Dermatol 2001; 144: 583-586.
31. Davison SC, Morris-Jones R, Powles AV, Fry L. Change of treatment from cyclosporin to mycophenolate mofetil in severe psoriasis. Br J Dermatol 2000; 143: 405-407.
32. Dauden E, Sanchez-Peinado C, Ruiz-Genao D, Garcia FV, Onate MJ, Garcia-Diez A. Plasma trough levels of mycophenolic acid do not correlate with efficacy and safety of mycophenolate mofetil in psoriasis. Br J Dermatol 2004; 150: 132-135.
33. Ameen M, Smith HR, Barker JN. Combined mycophenolate mofetil and cyclosporin therapy for severe recalcitrant psoriasis. Clin Exp Dermatol 2001; 26: 480-483.
34. Geilen CC, Tebbe B, Garcia BC, Krengel S, Orfanos CE. Successful treatment of erythrodermic psoriasis with mycophenolate mofetil. Br J Dermatol 1998; 138: 1101-1102.
35. Grundmann-Kollmann M, Mooser G, Schraeder P et al. Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil. J Am Acad Dermatol 2000; 42: 835-837.
36. Tong DW, Walder BK. Widespread plaque psoriasis responsive to mycophenolate mofetil. Australas J Dermatol 1999; 40: 135-137.
37. Wohlrab J, Jahn K, Plaetzer M, Neubert R, Marsch WC. Topical application of mycophenolate mofetil in plaque-type psoriasis. Br J Dermatol 2001; 144: 1263-1264.
38. Neuber K, Schwartz I, Itschert G, Dieck AT. Treatment of atopic eczema with oral mycophenolate mofetil. Br J Dermatol 2000; 143: 385-391.
39. Grundmann-Kollmann M, Korting HC, Behrens S et al. Successful treatment of severe refractory atopic dermatitis with mycophenolate mofetil. Br J Dermatol 1999; 141: 175-176.
40. Grundmann-Kollmann M, Podda M, Ochsendorf F, Boehncke WH, Kaufmann R, Zollner TM. Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch Dermatol 2001; 137: 870-873.
41. Hansen ER, Buus S, Deleuran M, Andersen KE. Treatment of atopic dermatitis with mycophenolate mofetil. Br J Dermatol 2000; 143: 1324-1326.
42. Benez A, Fierlbeck G. Successful long-term treatment of severe atopic dermatitis with mycophenolate mofetil. Br J Dermatol 2001; 144: 638-639.
43. Adu D, Cross J, Jayne DR. Treatment of systemic lupus erythematosus with mycophenolate mofetil. Lupus 2001; 10: 203-208.
44. Riskalla MM, Somers EC, Fatica RA, McCune WJ. Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus. J Rheumatol 2003; 30: 1508-1512.
45. Gaubitz M, Schorat A, Schotte H, Kern P, Domschke W. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 1999; 8: 731-736.
46. Schanz S, Ulmer A, Rassner G, Fierlbeck G. Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. Br J Dermatol 2002; 147: 174-178.
47. Goyal S, Nousari HC. Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil. J Am Acad Dermatol 2001; 45: 142-144.
48. Boehm I, Bieber T. Chilblain lupus erythematosus Hutchinson: successful treatment with mycophenolate mofetil. Arch Dermatol 2001; 137: 235-236.
49. Nousari HC, Lynch W, Anhalt GJ, Petri M. The effectiveness of mycophenolate mofetil in refractory pyoderma gangrenosum. Arch Dermatol 1998; 134: 1509-1511.
50. Hohenleutner U, Mohr VD, Michel S, Landthaler M. Mycophenolate mofetil and cyclosporin treatment for recalcitrant pyoderma gangrenosum. Lancet 1997; 350: 1748.
51. Michel S, Hohenleutner U, Mohr V, Landthaler M. Therapy-resistant pyoderma gangrenosum - treatment with mycophenolate mofetil and cyclosporine A. Hautarzt 1999; 50: 428-431.
52. Wollina U, Karamfilov T. Treatment of recalcitrant ulcers in pyoderma gangrenosum with mycophenolate mofetil and autologous keratinocyte transplantation on a hyaluronic acid matrix. J Eur Acad Dermatol Venereol 2000; 14: 187-190.
53. Busca A, Saroglia EM, Lanino E et al. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation. Bone Marrow Transplant 2000; 25: 1067-1671.
54. Basara N, Blau WI, Romer E et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant 1998; 22: 61-65.
55. Gelber AC, Nousari HC, Wigley FM. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol 2000; 27: 1542-1545.
56. Tausche AK, Meurer M. Mycophenolate mofetil for dermatomyositis. Dermatology 2001; 202: 341-343.
57. Waldman MA, Callen JP. Mycophenolate mofetil treatment of a patient with hyperglobulinemic purpura. J Am Acad Dermatol 2004; 51: 667-669.
58. Nousari HC, Goyal S, Anhalt GJ. Successful treatment of resistant hypertrophic and bullous lichen planus with mycophenolate mofetil. Arch Dermatol 1999; 135: 1420-1421.
59. Frieling U, Bonsmann G, Schwarz T, Luger TA, Beissert S. Treatment of severe lichen planus with mycophenolate mofetil. J Am Acad Dermatol 2003; 49: 1063-1066.
60. Davis MD, Rogers III RS, Pittelkow MR. Recurrent erythema multiforme/Stevens-Johnson syndrome: response to mycophenolate mofetil. Arch Dermatol 2002; 138: 1547-1550.
61. Hussein MM, Mooij JM, Roujouleh HM. Regression of posttransplant Kaposi sarcoma after discontinuing cyclosporin and giving mycophenolate mofetil instead. Nephrol Dial Transplant 2000; 15: 1103-1104.
62. Gomez E, Aguado S, Rodriguez M, Alvarez-Grande J. Kaposi's sarcoma after renal transplantation - disappearance after reduction of immunosuppression and reappearance 7 years later after start of mycophenolate mofetil treatment. Nephrol Dial Transplant 1998; 13: 3279-3280.
63. Pickenacker A, Luger TA, Schwarz T. Dyshidrotic eczema treated with mycophenolate mofetil. Arch Dermatol 1998; 134: 378-379.
64. Kouba DJ, Mimouni D, Rencic A, Nousari HC. Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis. Br J Dermatol 2003; 148: 147-148.
65. Reinhard G, Lohmann F, Uerlich M, Bauer R, Bieber T. Successful treatment of ulcerated necrobiosis lipoidica with mycophenolate mofetil. Acta Derm Venereol 2000; 80: 312-313.
66. Enk AH, Knop J. Treatment of relapsing idiopathic nodular panniculitis (Pfeifer-Weber-Christian disease) with mycophenolate mofetil. J Am Acad Dermatol 1998; 39: 508-509.
67. Boyd AS. Use of mycophenolate mofetil in erythema nodosum. J Am Acad Dermatol 2002; 47: 968-969.
68. Worm M, Sterry W, Kolde G. Mycophenolate mofetil is effective for maintenance therapy of hypocomplementaemic urticarial vasculitis. Br J Dermatol 2000; 143: 1324.
69. Kose O, Safali M, Bulent TH, Gur AR. Mycophenolate mofetil in extensive Alopecia areata: no effect in seven patients. Dermatology 2004; 209: 69-70.
70. Nousari HC, Anhalt GJ, Morison WL. Mycophenolate in psoralen-UV-A desensitization therapy for chronic actinic dermatitis. Arch Dermatol 1999; 135: 1128-1129.
71. Liu V, Mackool BT. Mycophenolate in dermatology. J Dermatolog Treat 2003; 14: 203-211.
72. Apostolou T, Tsagalis G, Koutroubas G, Hadjiconstantinou V, Drakopoulos S. Mycophenolate mofetil and oral ulcerations. Transplantation 2004; 77: 1911-1912.
73. Rault R. Mycophenolate-associated onycholysis. Ann Intern Med 2000; 133: 921-922.
74. Semhoun-Ducloux S, Ducloux D, Miguet JP. Mycophenolate mofetil-induced dyshidrotic eczema. Ann Intern Med 2000; 132: 417.
75. Satchell AC, Barnetson RS. Staphylococcal septicaemia complicating treatment of atopic dermatitis with mycophenolate. Br J Dermatol 2000; 143: 202-203.
76. Neyts J, De Clercq E. Mycophenolate mofetil strongly potentiates the anti-herpesvirus activity of acyclovir. Antiviral Res 1998; 40: 53-56.
77. Gimenez F, Foeillet E, Bourdon O et al. Evaluation of pharmacokinetic interactions after oral administration of mycophenolate mofetil and valaciclovir or aciclovir to healthy subjects. Clin Pharmacokinet 2004; 43: 685-692.
78. Nousari HC, Anhalt GJ. The role of mycophenolate mofetil in the management of pemphigus. Arch Dermatol 1999; 135: 853-854.